The following note is from the American Academy of Cardiology. Please click on the links within that will take you to these two informational bulletins:

- COVID-19 Clinical Guidance for the Cardiovascular Care Team
- HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19

**ACC's COVID-19 Hub Helps Members Help and Heal**

As COVID-19 continues to spread, the ACC is working to help members on the front lines prepare for and manage the virus so they can do what they do best: help and heal patients. ACC's new COVID-19 Hub curates ACC clinical guidance – including an [ACC Clinical Bulletin](https://example.com), an [HFSA/ACC/AHA statement](https://example.com) addressing concerns on the use of renin angiotensin aldosterone system antagonists in COVID-19 patients, an [ACC Interventional Council/SCAI statement](https://example.com) addressing cath lab considerations, and more – clinical perspectives and front-line experience; regulatory and reimbursement updates; and more.

[Visit the hub](https://example.com) for continuously updated resources for cardiac-specific preparedness. In addition, a [COVID-19 discussion category](https://example.com) has been created on Member Hub, ACC's online community, so that you can connect with colleagues who are also on the frontlines of combating the effects of the pandemic.